Skip to the beginning of the images gallery

Recombinant FAP Antibody - Primary antibody, specific to Fibroblast activation protein, alpha, Rabbit IgG

ExactAb™
Recombinant
Validated
1.5 mg/mL

Features and benefits

Short Overview:
Recombinant; Rabbit anti Human FAP Antibody; WB; Unconjugated
Species reactivity(Reacts with): Human
Isotype: Rabbit IgG

Application:

Item Number

Ab103512

Grouped product items
SKU	Size	Availability	Price
Ab103512-10μl	10μl	In stock	$66.90
Ab103512-50μl	50μl	In stock	$199.90
Ab103512-100μl	100μl	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$299.90
Ab103512-1ml	1ml	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,399.90

Recombinant; Rabbit anti Human FAP Antibody; WB; Unconjugated

View related series

Accession#:Q12884 DPPIV FAP FAP alpha Gene ID:2191

Basic Description

Product Name	Recombinant FAP Antibody - Primary antibody, specific to Fibroblast activation protein, alpha, Rabbit IgG
Synonyms	170 kDa melanoma membrane bound gelatinase antibody; 170 kDa melanoma membrane-bound gelatinase antibody; DPPIV antibody; FAP antibody; FAPA antibody; Fibroblast activation protein alpha antibody; Integral membrane serine protease antibody; SEPR_HUMAN ant
Specifications & Purity	ExactAb™, Validated, Recombinant, 1.5 mg/mL
Host species	Rabbit
Specificity	Fibroblast activation protein, alpha
Immunogen	A synthetic peptide derived from human FAP (AA 1-250)
Positive Control	WB: HeLa cell lysate.
Conjugation	Unconjugated
Grade	ExactAb™, Recombinant, Validated
Product Description	Rabbit anti Human FAP Antibody, Recombinant, could be used for WB and so on. Application WB: 1/500-1/2000 Protein Function In association with DPP4 is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May have a role in tissue remodeling during development and wound healing, and may contribute to invasiveness in malignant cancers.

Product Properties

Isotype	Rabbit IgG
Light Chain Type	kappa
SDS-PAGE	150 kDa
Purification Method	Protein A purified
Form	Liquid
Concentration	1.5 mg/mL
Storage Temp	Store at -20°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at 4℃ short term (1-2 weeks). Store at -20℃ long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant FAP Antibody (Ab103512) - Western Blot
All lanes: Recombinant FAP Antibody (Ab103512) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 88 kDa
Observed band size: 95 kDa
Exposure time: 28.8 s

Associated Targets

FAP Tchem Prolyl endopeptidase FAP 0 Activities

Discover Target: FAP

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application

Application	Dilution info
WB	1/500-1/2000

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0202722	Certificate of Analysis	Feb 05, 2024	Ab103512
ZJ24F0202721	Certificate of Analysis	Feb 05, 2024	Ab103512

References

1. Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D et al.. (2014) Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.. J Med Chem, 57 (8): (3205-12). [PMID:24660890]
2. Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, Wu Y, Zhou Y, Sudmeier JL, Sanford DG et al.. (2013) Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.. J Med Chem, 56 (9): (3467-77). [PMID:23594271]
3. Mohane Selvaraj Coumar,Chung-Nien Chang,Chiung-Tong Chen,Xin Chen,Chia-Hui Chien,Ting-Yueh Tsai,Jai-Hong Cheng,Hsin-Yi Wu,Chia-Hung Han,Ssu-Hui Wu,Yu-Wen Huang,Tsu Hsu,Li-Jen Hsu,Yu-Sheng Chao,Hsing-Pang Hsieh,Weir-Torn Jiaang. (2006-12-30) 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.. Bioorganic & medicinal chemistry letters, 17 ((5)): (1274-1279). [PMID:17194587]
4. Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, McClure LD, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soeller WC, Soglia CB, Treadway JL, VanVolkenburg MA, Wang H, Wilder DC, Olson TV.. (2006) cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.. J Med Chem, 49 (11): (3068-3076). [PMID:16722626]
5. Pei Z, Li X, Longenecker K, von Geldern TW, Wiedeman PE, Lubben TH, Zinker BA, Stewart K, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Long M, Wells H, Kempf-Grote AJ, Madar DJ, McDermott TS, Bhagavatula L, Fickes MG, Pireh D, Solomon LR, Lake MR, Edalji R, Fry EH, Sham HL, Trevillyan JM.. (2006) Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.. J Med Chem, 49 (12): (3520-3535). [PMID:16759095]
6. Edmondson SD, Mastracchio A, Mathvink RJ, He J, Harper B, Park YJ, Beconi M, Di Salvo J, Eiermann GJ, He H, Leiting B, Leone JF, Levorse DA, Lyons K, Patel RA, Patel SB, Petrov A, Scapin G, Shang J, Roy RS, Smith A, Wu JK, Xu S, Zhu B, Thornberry NA, Weber AE.. (2006) (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.. J Med Chem, 49 (12): (3614-3627). [PMID:16759103]
7. Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL, Trevillyan JM.. (2006) Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.. J Med Chem, 49 (21): (6416-6420). [PMID:17034148]
8. Wright SW, Ammirati MJ, Andrews KM, Brodeur AM, Danley DE, Doran SD, Lillquist JS, Liu S, McClure LD, McPherson RK, Olson TV, Orena SJ, Parker JC, Rocke BN, Soeller WC, Soglia CB, Treadway JL, Vanvolkenburg MA, Zhao Z, Cox ED.. (2007) (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.. Bioorg Med Chem Lett, 17 (20): (5638-5642). [PMID:17822893]
9. Backes BJ, Longenecker K, Hamilton GL, Stewart K, Lai C, Kopecka H, von Geldern TW, Madar DJ, Pei Z, Lubben TH, Zinker BA, Tian Z, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Kempf-Grote AJ, Black-Schaefer C, Sham HL, Trevillyan JM.. (2007) Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.. Bioorg Med Chem Lett, 17 (7): (2005-2012). [PMID:17276063]
10. Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G.. (2009) Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.. J Med Chem, 52 (2): (358-368). [PMID:19093877]
11. Havale SH, Pal M.. (2009) Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.. Bioorg Med Chem, 17 (5): (1783-1802). [PMID:19217790]
12. Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC, Piotrowski DW.. (2009) (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.. Bioorg Med Chem Lett, 19 (7): (1991-1995). [PMID:19275964]
13. Andrews KM, Beebe DA, Benbow JW, Boyer DA, Doran SD, Hui Y, Liu S, McPherson RK, Neagu C, Parker JC, Piotrowski DW, Schneider SR, Treadway JL, VanVolkenberg MA, Zembrowski WJ.. (2011) 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.. Bioorg Med Chem Lett, 21 (6): (1810-1814). [PMID:21324688]
14. Sutton JM, Clark DE, Dunsdon SJ, Fenton G, Fillmore A, Harris NV, Higgs C, Hurley CA, Krintel SL, MacKenzie RE, Duttaroy A, Gangl E, Maniara W, Sedrani R, Namoto K, Ostermann N, Gerhartz B, Sirockin F, Trappe J, Hassiepen U, Baeschlin DK.. (2012) Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.. Bioorg Med Chem Lett, 22 (3): (1464-1468). [PMID:22177783]
15. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H.. (2012) Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.. Bioorg Med Chem, 20 (19): (5864-5883). [PMID:22938786]
16. Biftu T, Qian X, Chen P, Feng D, Scapin G, Gao YD, Cox J, Roy RS, Eiermann G, He H, Lyons K, Salituro G, Patel S, Petrov A, Xu F, Xu SS, Zhang B, Caldwell C, Wu JK, Lyons K, Weber AE.. (2013) Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].. Bioorg Med Chem Lett, 23 (19): (5361-5366). [PMID:23972441]
17. Wang J, Feng Y, Ji X, Deng G, Leng Y, Liu H.. (2013) Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.. Bioorg Med Chem, 21 (23): (7418-7429). [PMID:24153396]
18. Wang S, Su M, Wang J, Li Z, Zhang L, Ji X, Li J, Li J, Liu H.. (2014) (R)-3-amino-1-((3aS,7aS)-octahydro-1H-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: design, synthesis, biological evaluation, and molecular modeling.. Bioorg Med Chem, 22 (23): (6684-6693). [PMID:25457126]
19. Wu WL, Hao J, Domalski M, Burnett DA, Pissarnitski D, Zhao Z, Stamford A, Scapin G, Gao YD, Soriano A, Kelly TM, Yao Z, Powles MA, Chen S, Mei H, Hwa J.. (2016) Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.. ACS Med Chem Lett, 7 (5): (498-501). [PMID:27190600]
20. Jung HJ,Nam EH,Park JY,Ghosh P,Kim IS. (2021) Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.. Bioorg Med Chem Lett, 37 (127846-127846). [PMID:33571650]
21. Aoyama, A A and Chen, W T WT.. (1990) A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2172980]
22. Rettig, W J WJ and 7 more authors.. (1994) Fibroblast activation protein: purification, epitope mapping and induction by growth factors.. International journal of cancer, (1): [PMID:7519584]
23. Scanlan, M J MJ and 7 more authors.. (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.. Proceedings of the National Academy of Sciences of the United States of America, (7): [PMID:7911242]
24. Monsky, W L WL and 6 more authors.. (1994) A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells.. Cancer research, (1): [PMID:7923219]
25. Piñeiro-Sánchez, M L ML and 7 more authors.. (1997) Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.. The Journal of biological chemistry, (21): [PMID:9065413]
26. Goldstein, L A LA and 6 more authors.. (1997) Molecular cloning of seprase: a serine integral membrane protease from human melanoma.. Biochimica et biophysica acta, (10): [PMID:9247085]
27. Levy, M T MT and 7 more authors.. (1999) Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis.. Hepatology (Baltimore, Md.), [PMID:10347120]
28. Mueller, S C SC and 8 more authors.. (1999) A novel protease-docking function of integrin at invadopodia.. The Journal of biological chemistry, (27): [PMID:10455171]
29. Park, J E JE and 5 more authors.. (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.. The Journal of biological chemistry, (17): [PMID:10593948]
30. Goldstein, L A LA and Chen, W T WT.. (2000) Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform.. The Journal of biological chemistry, (28): [PMID:10644713]
31. Artym, Vira V VV, Kindzelskii, Andrei L AL, Chen, Wen-Tien WT and Petty, Howard R HR.. (2002) Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton.. Carcinogenesis, [PMID:12376466]
32. Lee, Kyung N KN, Jackson, Kenneth W KW, Christiansen, Victoria J VJ, Chung, Keun H KH and McKee, Patrick A PA.. (2004) A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion.. Blood, (15): [PMID:14751930]
33. Aertgeerts, Kathleen K and 11 more authors.. (2005) Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha.. The Journal of biological chemistry, (20): [PMID:15809306]
34. Hillier, Ladeana W LW and 121 more authors.. (2005) Generation and annotation of the DNA sequences of human chromosomes 2 and 4.. Nature, (7): [PMID:15815621]
35. Wang, Xin Maggie XM, Yu, Denise Ming Tse DM, McCaughan, Geoffrey W GW and Gorrell, Mark D MD.. (2005) Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line.. Hepatology (Baltimore, Md.), [PMID:16175601]
36. Lee, Kyung N KN and 5 more authors.. (2006) Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.. Blood, (15): [PMID:16223769]
37. Liu, Tao T and 6 more authors.. () Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952]
38. Edosada, Conrad Yap CY and 9 more authors.. (2006) Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.. The Journal of biological chemistry, (17): [PMID:16410248]
39. Edosada, Conrad Yap CY and 6 more authors.. (2006) Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.. FEBS letters, (6): [PMID:16480718]
40. Ghersi, Giulio G and 5 more authors.. (2006) The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices.. Cancer research, (1): [PMID:16651416]
41. Bauer, Stefan S and 11 more authors.. (2006) Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.. Arthritis research & therapy, [PMID:17105646]
42. Meadows, Sarah A SA and 7 more authors.. (2007) Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.. Biochemistry, (17): [PMID:17381073]
43. Aggarwal, Saurabh S and 7 more authors.. (2008) Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.. Biochemistry, (22): [PMID:18095711]
44. Mentlein, Rolf R, Hattermann, Kirsten K, Hemion, Charles C, Jungbluth, Achim A AA and Held-Feindt, Janka J.. (2011) Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors.. Biological chemistry, [PMID:20707604]
45. Huang, Chih-Hsiang CH and 9 more authors.. (2011) Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate.. Journal of biochemistry, [PMID:21288888]
46. Keane, Fiona M FM, Nadvi, Naveed A NA, Yao, Tsun-Wen TW and Gorrell, Mark D MD.. (2011) Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α.. The FEBS journal, [PMID:21314817]
47. Keane, Fiona M FM and 25 more authors.. (2013) Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs.. FEBS open bio, [PMID:24371721]
48. Osborne, Brenna B and 11 more authors.. (2014) A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation.. Biochimica et biophysica acta, [PMID:24717288]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.